https://www.live-feeds.com/feed/inhibrx-claims-first-win-for-long-sought-immunotherapy-targetContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/inhibrx-claims-first-win-for-long-sought-immunotherapy-targethttps://www.live-feeds.com/feed/inhibrx-claims-first-win-for-long-sought-immunotherapy-target#u63714Thu, 10 Sep 2026 08:16:07 +0000Inhibrx reports that its drug INBRX-106 nearly doubles response rates and achieves an interim median progression-free survival of 9.6 months in a Phase 2 head and neck squamous cell carcinoma study. The company claims this milestone represents the first clinical win for a long-sought immunotherapy target involving an OX40 agonist. The chief executive officer states that the progression-free survival data leave no question about the durability of the treatment, while also opening the door for potential cancer vaccine combinations.Why it mattersTargeting OX40 has long been sought in immunotherap